Ray Horwitz, DO
Psychiatry · Atlanta, GANPI 1376640953
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,250 of the $64,346 with a category attached, or 75.0%. Supernus Pharmaceuticals, Inc. accounts for 88.2% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2023 at $20,636 and has fallen 93.1% since, to $1,418 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 474 payments — averaging $135.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Supernus Pharmaceuticals, Inc.$57K
- AbbVie$995
- Otsuka America Pharmaceutical, Inc.$911
- Takeda Pharmaceuticals U.S.A., Inc.$795
- Avanir Pharmaceuticals, Inc.$771
- Lundbeck LLC$748
- plus $3K from 20 others
What the payments were for
- Speaking & faculty fees$48,25075%
- Travel & lodging$6,12710%
- Food & beverage$9,96315%
- Education$70%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Supernus Pharmaceuticals, Inc. | 125 | $56,751 |
| AbbVie(2 entities) | 52 | $995 |
| Otsuka America Pharmaceutical, Inc. | 40 | $911 |
| Takeda Pharmaceuticals U.S.A., Inc. | 33 | $795 |
| Avanir Pharmaceuticals, Inc. | 36 | $771 |
| Lundbeck LLC | 40 | $748 |
| Axsome Therapeutics, Inc. | 18 | $626 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $477 |
| Johnson & Johnson | 14 | $465 |
| Vanda Pharmaceuticals Inc. | 22 | $447 |
| Jazz Pharmaceuticals Inc. | 9 | $202 |
| Neos Therapeutics, LP | 8 | $146 |
| Alkermes, Inc. | 7 | $139 |
| Noven Therapeutics, LLC | 7 | $136 |
| Almatica Pharma LLC | 6 | $122 |
| Eisai Inc. | 7 | $114 |
| Corium, LLC | 5 | $102 |
| Ironshore Pharmaceuticals Inc. | 4 | $78 |
| Tris Pharma Inc | 3 | $65 |
| Bausch Health US, LLC | 3 | $51 |
| Adlon Therapeutics L.p. | 3 | $50 |
| Teva Pharmaceuticals USA, Inc. | 4 | $47 |
| Shire North American Group Inc | 3 | $39 |
| Aytu Biopharma, Inc. | 1 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Neuronetics, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$64,346 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuedextaDextromethorphan Hbr/Quinidine | 12 | $18,989 |
| VraylarCariprazine Hcl | 13 | $18,844 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 362 | $11,853 |
| BelsomraSuvorexant | 15 | $6,610 |
| Alprazolam | 613 | $4,332 |
| Lurasidone Hcl | 14 | $1,779 |
| Quetiapine Fumarate | 96 | $1,668 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 30 | $988 |
| Duloxetine Hcl | 90 | $955 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 27 | $908 |
| Diazepam | 56 | $764 |
| Ziprasidone Hcl | 25 | $679 |
| Paroxetine Hcl | 22 | $609 |
| Divalproex Sodium ErDivalproex Sodium | 30 | $589 |
| Zolpidem Tartrate | 116 | $587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Avanir Pharmaceuticals, Inc.Nuedexta | $771 | $18,98912 claims |
| AbbVieVraylar | $995 | $18,84413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Atlanta
- David PurselleAtlanta$307K
- Michael BurkeAtlanta$217K
- Bryon EvansAtlanta$211K
- Kerry ResslerAtlanta$196K
- Patricio Riva PosseAtlanta$122K
- Boadie DunlopAtlanta$61K
- Zohaib HaqueAtlanta$49K
- Raymond KotwickiAtlanta$44K
- Joseph BergerAtlanta$24K
- Dwight OwensAtlanta$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.